Neuro-Bio is a biotech company focused on addressing neurodegenerative diseases, particularly Alzheimer's disease (AD). The company has identified a novel toxic molecule, T14, which plays a significant role in the degeneration of specific brain cells associated with AD. This discovery has led to the development of innovative therapeutic strategies, including a potential drug that blocks T14 and a biomarker for early diagnosis of AD before symptoms manifest. Neuro-Bio's research has established a clear link between T14 and the pathology of Alzheimer's, utilizing a unique animal model to further explore the effects of this peptide and its receptor.

The team at Neuro-Bio comprises experienced scientists with diverse expertise in neuroscience, pharmacology, and biomarker development. They employ advanced techniques such as optical and electrophysiological methods to screen and identify promising compounds for Alzheimer's therapy. The collaborative efforts of the team aim to translate basic neurobiological findings into effective treatments, showcasing a commitment to innovative research that could significantly impact the management of neurodegenerative diseases.

United Kingdom

‘Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration. This new distinct mechanism is being exploited by Neuro-Bio to discover first-in-class drugs to treat Alzheimer's disease and to develop a biomarker as a companion diagnostic'.

Neuro-Bio

Company Details